Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.

ABSTRACT:

Objective

To evaluate the influence of the single nucleotide polymorphism rs1080985 in the cytochrome P450 2D6 (CYP2D6) gene on the efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD).

Methods

This was a multicenter, prospective cohort study of 127 white patients with AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association Work Group criteria. Patients were treated with donepezil 5-10 mg/daily for 6 months. Cognitive and functional statuses were evaluated at baseline and at 6-month follow-up. Response to therapy was defined according to the National Institute for Health and Clinical Excellence criteria. Compliance and drug-related adverse events were also ev

SUBMITTER: Pilotto A 

PROVIDER: S-EPMC2739607 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature